Kalaris Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Kalaris Therapeutics Depreciation & Amortization Growth & History (KLRS)
Kalaris Therapeutics's depreciation and amortization was $13,000 for fiscal 2025.
View full Kalaris Therapeutics company overviewKalaris Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13,000 | $13,000 | — |
| 2024 | 2024-12-31 | $0 | −$398,000 | — |
| 2023 | 2023-12-31 | $398,000 | −$325,000 | −44.95% |
| 2022 | 2022-12-31 | $723,000 | $534,000 | +282.54% |
| 2021 | 2021-12-31 | $189,000 | $116,000 | +158.90% |
| 2020 | 2020-12-31 | $73,000 | $54,000 | +284.21% |
| 2019 | 2019-12-31 | $19,000 | — | — |
Kalaris Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $10,000 | $10,000 | — |
| Q1 2026 | 2026-03-31 | $10,000 | $10,000 | — |
| Q4 2025 | 2025-12-31 | $10,000 | — | — |
| Q3 2025 | 2025-09-30 | $3,000 | — | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q3 2023 | 2023-09-30 | $86,000 | $1,000 | +1.18% |
| Q2 2023 | 2023-06-30 | $85,000 | −$1,000 | −1.16% |
| Q1 2023 | 2023-03-31 | $86,000 | −$380,000 | −81.55% |
| Q3 2022 | 2022-09-30 | $85,000 | $41,000 | +93.18% |
| Q2 2022 | 2022-06-30 | $86,000 | $53,000 | +160.61% |
| Q1 2022 | 2022-03-31 | $466,000 | $448,000 | +2488.89% |
| Q3 2021 | 2021-09-30 | $44,000 | $26,000 | +144.44% |
| Q2 2021 | 2021-06-30 | $33,000 | $14,000 | +73.68% |
| Q1 2021 | 2021-03-31 | $18,000 | $0 | 0.00% |
| Q3 2020 | 2020-09-30 | $18,000 | — | — |
| Q2 2020 | 2020-06-30 | $19,000 | — | — |
| Q1 2020 | 2020-03-31 | $18,000 | — | — |
Kalaris Therapeutics depreciation and amortization trends
Over the last five fiscal years, Kalaris Therapeutics's depreciation and amortization decreased from $73,000 to $13,000, a change of −$60,000. The latest reported quarter, Q2 2026, shows $10,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kalaris Therapeutics source filings ↗